.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,261,889

« Back to Dashboard

Details for Patent: 7,261,889

Title:Local anesthetic methods and kits
Abstract: Methods of reversing local anesthesia are disclosed. The methods comprise administering a local anesthetic and alpha adrenergic receptor agonist to induce local anesthesia followed by reversing anesthesia with a low dose of an alpha adrenergic receptor antagonist. Also disclosed are kits comprising a local anesthetic, an alpha adrenergic receptor agonist and a low dose of an alpha adrenergic receptor antagonist.
Inventor(s): Weber; Eckard (San Diego, CA), Katz; Howard I. (La Jolla, CA)
Assignee: Novalar Pharmaceuticals, Inc. (San Diego, CA)
Filing Date:Mar 17, 2005
Application Number:11/081,640
Claims:1. A kit comprising a carrier having in close confinement therein two or more containers, wherein a first container contains an anesthetic agent and optionally an alpha adrenergic receptor agonist and a second container contains a unit dose of a composition, said unit dose comprising between about 0.0018 mg and about 0.45 mg phentolamine mesylate or a molar equivalent of another alpha adrenergic receptor antagonist.

2. The kit of claim 1, wherein said another alpha adrenergic receptor antagonist is selected from the group consisting of phentolamine, phentolamine hydrochloride, tolazoline, yohimbine, rauwolscine, doxazosine, labetalol, prazosine, tetrazosine and trimazosine.

3. The kit of claim 1, wherein said anesthetic agent is selected from the group consisting of lidocaine, polocaine, etidocaine, lignocaine, xylocaine, novocaine, carbocaine, procaine, prilocaine, bupivacaine, cinchocaine, and mepivacaine.

4. The kit of claim 1, wherein said alpha adrenergic receptor agonist is selected from the group consisting of levonordefrin, epinephrine and norepinephrine.

5. The kit of claim 1, wherein said second container has a volume of between 1.6 mL and 1.8 mL.

6. The kit of claim 1, wherein said second container is a CARPULE.

7. The kit of claim 1, wherein said second container fits into a standard dental local anesthetic syringe.

8. The kit of claim 1, wherein said anesthetic agent and said alpha adrenergic receptor agonist are in said first container.

9. The kit of claim 8, wherein said anesthetic agent and said alpha adrenergic agonist are in separate containers.

10. The kit of claim 1, wherein said unit dose comprises between about 0.09 mg and about 0.45 mg phentolamine mesylate or a molar equivalent of another alpha adrenergic receptor antagonist.

11. A kit comprising a carrier having in close confinement therein two or more containers, wherein a first container contains an anesthetic agent and optionally an alpha adrenergic receptor agonist and a second container contains a solution comprising an alpha adrenergic receptor antagonist at a concentration of from about 0.001 mg/mL to about 0.25 mg/mL.

12. The kit of claim 11, wherein said alpha adrenergic receptor antagonist is selected from the group consisting of phentolamine mesylate, phentolamine, phentolamine hydrochloride, tolazoline, yohimbine, rauwolscine, doxazosine, labetalol, prazosine, tetrazosine and trimazosine.

13. The kit of claim 11, wherein said anesthetic agent is selected from the group consisting of lidocaine, polocaine, etidocaine, lignocaine, xylocaine, novocaine, carbocaine, procaine, prilocaine, bupivacaine, cinchocaine, and mepivacaine.

14. The kit of claim 11, wherein said alpha adrenergic receptor agonist is selected from the group consisting of levonordefrin, epinephrine and norepinephrine.

15. The kit of claim 11, wherein said second container has a volume of between 1.6 mL and 1.8 mL.

16. The kit of claim 11, wherein said second container is a CARPULE.

17. The kit of claim 11, wherein said anesthetic agent and said alpha adrenergic receptor agonist are in said first container.

18. The kit of claim 11, wherein said anesthetic agent and said alpha adrenergic agonist are in separate containers.

19. The kit of claim 11, wherein said alpha adrenergic receptor antagonist is present at a concentration of about 0.05 mg/mL to about 0.25 mg/mL.

20. The kit of claim 11, wherein said alpha adrenergic receptor antagonist is present at a concentration of about 0.25 mg/mL.

21. The kit of claim 11, wherein said second container comprises a dose of an alpha adrenergic receptor antagonist of between about 0.0018 mg to about 0.45 mg.

22. The kit of claim 21, wherein said dose is between about 0.09 mg to about 0.45 mg.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc